For example, in DLBCL, the OTUD3 inhibitor Rupatadine competitively bond to OTUD3 to block PD-L1 deubiquitination, promoting its proteasomal degradation, thereby alleviating PD-1/PD-L1-mediated immune suppression and enhancing anti-tumor T-cell activity (196). The gene discussed is OTUD3; the disease is neoplasm.